A risk-based biological evaluation per ISO 10993 is the first step. Chemical characterization according to ISO 10993-18, extraction design per ISO 10993-12, and toxicological risk assessment following ISO 10993-17 form the analytical foundation. For ELO-modified PVC, simulated use extractables/leachables studies should employ multiple media that reflect clinical contact: purified water or physiological saline (polar), 10–50% ethanol or isopropanol/water (semi-polar), and lipophilic simulants (e.g., vegetable oil, iso-octane) to probe worst-case migration into lipid emulsions and blood components. Test conditions typically include room temperature, elevated temperature, or extended durations to simulate sterilization and shelf life. Analysis by gas chromatography–mass spectrometry (GC–MS), liquid chromatography–mass spectrometry (LC–MS), inductively coupled plasma mass spectrometry (ICP–MS), and headspace GC–MS provides a comprehensive chemical profile, and analytical evaluation thresholds (AETs) are established based on exposure assumptions.
Biocompatibility test batteries are then tailored according to contact type and duration: cytotoxicity (ISO 10993-5), sensitization and irritation (ISO 10993-10), systemic toxicity and pyrogenicity (as applicable) (ISO 10993-11), and blood compatibility for blood-contacting devices (ISO 10993-4). For devices such as blood bags or extracorporeal circuits, special attention is required for hemolysis, complement activation, and coagulation assessments. When ELO significantly affects plasticizer levels, extractables analysis should consider epoxy ring-opening products (e.g., chlorohydrins under acidic or chloride-rich conditions) and potential oxidation products, ensuring they do not exceed toxicologically concerning thresholds. In practice, well-controlled ELO quality (low acid value, low peroxide value, stable epoxy oxygen content) and conservative stabilization schemes can mitigate such risks.
Regulatory pathways vary by jurisdiction. In the EU, the Medical Device Regulation (MDR) requires justification and labeling for CMR/ED substances present above 0.1%. While ELO is not a phthalate, devices transitioning from DEHP-containing PVC to ELO-modified systems should document the underlying rationale and provide comparative risk assessments. Applicable product standards (for example, ISO 3826 for blood bag systems and ISO 8536 for infusion devices) specify material and performance requirements that indirectly influence formulation choices (e.g., plasticizer migration, transparency, tensile properties). In the United States, FDA premarket submissions typically include extractables/leachables data for plasticized PVC, as well as sterilization validation and shelf-life studies; the agency’s focus on phthalates in medical devices underscores a drive for safer alternatives and clear toxicological rationales.
Sterilization compatibility is critical for safety and regulatory confidence. Gamma and electron-beam irradiation can alter PVC chemistry; ELO’s HCl-scavenging characteristics may mitigate radiation-induced dehydrochlorination and discoloration, but extractables profiles should be reassessed after sterilization and accelerated aging. Ethylene oxide (EtO) sterilization raises other considerations: residual ethylene oxide/ethylene chlorohydrin must meet limits, and it must be demonstrated that ELO-containing matrices do not catalyze unexpected byproduct formation. Label claims (e.g., “phthalate-free” or “bio-based content”) must be substantiated and may require market certification of bio-based content (such as ASTM D6866) while ensuring risk communication is scientifically grounded.
Performance standards and biocompatibility are intertwined. Mechanical and optical properties (tensile strength, elongation, Shore hardness, haze, and color) should be verified before and after sterilization and aging to ensure ELO does not compromise functionality or increase patient risk through device failure or visibility issues. For drug-contacting components (for example, infusion sets used with lipid emulsions or solvent-based drugs), compatibility and adsorption studies are critical, since certain formulations may alter drug potency via plasticizer extraction or adsorption.
In summary, ELO can facilitate compliance by eliminating or reducing phthalates and by improving radiolytic stability; however, this does not obviate the need for comprehensive chemical and biological evaluation. Robust ISO 10993 procedures, extractables/leachables studies using relevant media, sterilization stability assessments, and transparent regulatory documentation are key to safely integrating ELO into medical-grade PVC and meeting global regulatory requirements.